The medical device company said the stroke treatment device is the latest iteration of its Trevo line, designed to remove the blood clots that cause ischemic stroke.
The Trevo Pro uses the Stentretriever technology developed by Concentric, for which Stryker paid $135 million in the autumn of 2011.
Stryker touted the "strong clinical results" from its Trevo 2 trial it presented at the 2012 European Stroke Conference in May, saying it "demonstrated the highest rate of revascularization in a randomized embolectomy stroke device trial" and achieved "significantly better post-procedure revascularization" than its sister device, Concentric’s Merci retriever.
The clearance is a much-needed win for Stryker’s neurovascular unit after an FDA ruling last week limiting the use of its Wingspan cranial stent to patients who don’t do well with drug therapy.
Stryker, which spent $1.5 billion on Boston Scientific‘s (NYSE:BSX) neurovascular business in October 2010, is competing with Covidien (NYSE:COV) and its Solitaire clot retrieval device, which won market approval in Brazil in July.